Abstract
The research on the pathogenesis of multiple myeloma (MM) and the wide application of new drugs have put forward further requirements for the detection methods and efficacy evaluation of MM. In the 2018 American Society of Hematology (ASH) Annual Meeting, low-dose CT was recommended instead of plain X-ray as a screening method for the skeletal involvement in newly diagnosed MM patients. In terms of treatment, the status of monoclonal antibodies in MM treatment was further consolidated, and the chimeric antigen receptor T cell (CAR-T) immunotherapy was fully developed. Key words: Multiple myeloma; Diagnosis; Immunotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
